Vertex Pharmaceuticals (NASDAQ: VRTX)
Vertex Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
The Ultimate Biotech Stock to Buy With $500 Right Now
2 No-Brainer Stocks to Buy Before the End of 2024
How to Invest in CRISPR Therapeutics Stock
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Got $500? 1 Biotech Stock to Buy and Hold Forever
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Regulators are reviewing what could become a multi-billion-dollar drug.
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Both stocks have made significant breakthroughs.
Vertex Pharmaceuticals Tops Q3 Estimates
The cystic fibrosis treatment leader's revenue and earnings exceeded expectations.
Valuation
Podcast Episodes
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Earnings Transcripts
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2024.
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2024.
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2024.
Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.